Completed PHASE2/PHASE3 INTERVENTIONAL NCT00116870

MARS - Monitored Atherosclerosis Regression Study

A Double-Blind, Placebo-Controlled Angiographic Study to Evaluate the Effect of Lovastatin on the Progression Rate of Atherosclerosis in the Coronary Arteries of Patients With Coronary Heart Disease

Sponsor: Merck Sharp & Dohme LLC

Conditions Atherosclerosis Coronary Artery Disease

Interventions lovastatin

Updated 6 times since 2017 Last updated: Dec 9, 2009 Started: Jun 30, 1985 Primary completion: Feb 29, 1992 Completion: Feb 29, 1992

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00116870, this PHASE2/PHASE3 trial focuses on Atherosclerosis and Coronary Artery Disease and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 6 times since 1985, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jun 1985

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: National Institute on Aging (NIA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States